Alaunos Therapeutics, Inc.
TCRT evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $3.8M
- Lead Asset:
- aln1003 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for TCRT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TCRT
Alaunos Therapeutics, Inc. (TCRT) is a biotechnology company focused on developing ALN1003, a preclinical non-hormonal oral small-molecule candidate for obesity and metabolic disorders, with no approved products or revenue as of mid-2026.
Key risk: Preclinical stage only
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$3.8M
Cash Runway
—
Lead Asset
aln1003 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 27 clinical trials for Alaunos Therapeutics, Inc..
Alaunos Therapeutics, Inc. (TCRT) is a biotechnology company focused on developing ALN1003, a preclinical non-hormonal oral small-molecule candidate for obesity and metabolic disorders, with no approved products or revenue as of mid-2026.
- Lead candidate ALN1003 is a preclinical non-hormonal, non-incretin small molecule for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [pipeline].
- As of 2026-06-30, the company reported cash & equivalents of $0.1M, zero revenue, a net loss of -$1.0M, and shareholders' equity of $0.7M [sec].
- In March 2026, Alaunos announced positive preclinical proof-of-concept data for ALN1003, showing dose-related body weight loss and favorable body composition changes in diet-induced obesity mouse models [news · published 2026-03-02].
- Updated preclinical data in May 2026 reported that ALN1003 demonstrated reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in obese mice [news · published 2026-05-26].
- The company has no disclosed clinical-stage programs; its earlier pipeline (e.g., Ad-RTS-hIL-12 for glioblastoma) appears to have been discontinued or deprioritized [catalyst].
What works
- ALN1003 targets a large and growing market (obesity and MASLD) with a non-hormonal, non-incretin mechanism that could differentiate it from GLP-1-based competitors [pipeline].
- Preclinical data consistently show multi-metric metabolic improvements (weight loss, fat mass reduction, insulin sensitivity, liver health) in diet-induced obese mice [news · published 2026-05-26].
- The company has publicly disclosed preclinical results and an investor presentation, indicating active communication of its science to potential partners or investors [news · published 2026-05-26].
What to weigh
- ALN1003 remains at the preclinical stage; it has not yet entered human clinical trials, and there is no disclosed timeline for IND filing or Phase 1 start [pipeline].
- As of 2026-06-30, the company had only $0.1M in cash and equivalents, which is likely insufficient to fund IND-enabling studies and clinical development without additional financing [sec].
- The company has zero revenue and a net loss of -$1.0M for the most recent reporting period, reflecting a cash-burning pre-revenue state [sec].
- Alaunos faces intense competition from well-capitalized companies (Novo Nordisk, Eli Lilly, Amgen, Pfizer, Viking Therapeutics, Structure Therapeutics) in the obesity space [pipeline].
From the filings
Quoted directly from source documents.
ALN1003 is a preclinical non-hormonal, non-incretin candidate for obesity and MASLD.
“Pipeline Candidate: aln1003 Indication: obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD) Phase: Preclinical Mechanism of Action: non-hormonal, non-incretin approach”
ALN1003 showed dose-related body weight loss and favorable body composition changes in DIO mice.
“The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model”
News · March 2, 2026
Updated preclinical data in May 2026 showed reductions in body weight and fat mass, improved insulin sensitivity, and improved liver health.
“ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice”
News · May 26, 2026
Risks & what to watch (4)›
Key risks
- Preclinical stage only — ALN1003 has not entered human trials; no IND filing or Phase 1 start date disclosed [pipeline].
- Cash runway critically low — Only $0.1M cash as of 2026-06-30; insufficient to fund IND-enabling studies without new financing [sec].
- Zero revenue, net loss — Company reported $0 revenue and -$1.0M net loss for the period ending 2026-06-30 [sec].
- Intense competitive landscape — Obesity space dominated by Novo Nordisk, Eli Lilly, Amgen, Pfizer, and others with approved or late-stage drugs [pipeline].
What to watch
- Whether Alaunos can secure additional financing or a partnership to fund IND-enabling studies for ALN1003 [sec].
- Any announcement of an IND filing or Phase 1 clinical trial start for ALN1003 [pipeline].
- Updates on preclinical data from ongoing non-GLP DIO mouse studies and any new formulation or manufacturing developments [news · published 2026-03-02].
- Competitive developments in the obesity space, particularly from well-funded rivals with similar non-incretin mechanisms [pipeline].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 3, 2026 · How we verify sources →
Run Alaunos Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alaunos Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.33 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 0.6%
- Days to cover
- 0.8
- Shares short
- 14,162
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TCRT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alaunos Therapeutics, Inc.?
Alaunos Therapeutics, Inc. (TCRT) is a biotechnology company focused on developing ALN1003, a preclinical non-hormonal oral small-molecule candidate for obesity and metabolic disorders, with no approved products or revenue as of mid-2026.
What is Alaunos Therapeutics, Inc.'s lead drug candidate?
Alaunos Therapeutics, Inc.'s most advanced tracked candidate is aln1003 (Preclinical) for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD).
Who is the CEO of Alaunos Therapeutics, Inc.?
Mr. Holger Weis CPA is the chief executive officer of Alaunos Therapeutics, Inc. (TCRT).
Where is Alaunos Therapeutics, Inc. headquartered?
Alaunos Therapeutics, Inc. (TCRT) is headquartered in Fort Lauderdale, FL, United States.
What therapeutic areas does Alaunos Therapeutics, Inc. focus on?
Alaunos Therapeutics, Inc. develops therapies across Oncology, Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.